CD274 and lung adenocarcinoma: As compared with EGFR/ALK-wild type lung adenocarcinoma patients, EGFR-mutant (aOR 0.74 [95% CI 0.53–1.03], P = 0.078 and 0.67 [95% CI 0.42–1.07], P = 0.094) and HER2-mutant (aOR 0.92 [95% CI 0.31–2.76], P = 0.886 and 0.42 [95% CI 0.05–3.35], P = 0.413) patients had a similarly low PD-L1 and strong PD-L1 positive rate.